The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
about
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionA Review of Currently Available Fenofibrate and Fenofibric Acid FormulationsA tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with Familial Hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.New frontiers in the treatment of diabetic dyslipidemiaEffects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular diseasePeripheral arterial tonometry for risk stratification in men with coronary artery disease2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represNo significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with familial hypercholesterolemia compared to usual care: results of a randomised controlled trialThe characteristics of dyslipidemia patients with different durations in Beijing: a cross-sectional study.Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes malesEmerging drugs for hyperlipidemia.Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance.Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization.Pistachio nut consumption modifies systemic hemodynamics, increases heart rate variability, and reduces ambulatory blood pressure in well-controlled type 2 diabetes: a randomized trial.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentAchievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyTreatment approaches for diabetes and dyslipidemiaChanges in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008.Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) studyEffect of intensive multifactorial treatment on the intima-media thickness of large arteries in patients with new-onset type 2 diabetes mellitus.A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.The perception and knowledge of cardiovascular risk factors among medical students.Glycated hemoglobin and associated risk factors in older adults.Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansThe atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females.Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient miceHDL, Atherosclerosis, and Emerging TherapiesLifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study.Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications.High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapyDevelopment of Antisense Drugs for Dyslipidemia.2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
P2860
Q21246041-82FAB028-97A0-4C0A-AA8A-668A78F2948EQ30048180-B9232578-0BA6-4AFF-BB4B-4B636E8FA66DQ33531339-F39158A8-FB44-4D3E-ADB8-9C16FF22F939Q33776194-9AFA256B-E13B-4E6B-B557-0F60F4612AC4Q33776236-6D9F22B6-8D3E-4B01-A22D-3F87F9DF901EQ33855092-F6B45772-C6B5-4153-858A-97160436883DQ34038387-CA9F40C3-2D72-492C-9009-8068CAFB8B08Q34046881-6E2E1E4E-87EA-4F67-A43A-80B09E4BCD50Q34227238-DEA0581D-8A6F-495A-9A43-90073744DA74Q34244128-46ACD7F8-241F-4BE8-8EDF-31B110BF2CF5Q34347027-71524F19-1931-4C0E-8994-9E5BBA9FBD9AQ34398065-78B39C7A-B7EA-4DF5-BAA1-AD1F20F3ECF4Q34486059-8EF6F90E-A64D-4034-B700-E9A457E58C11Q34619115-2516FB2E-177B-424C-BA44-F018F313BA74Q34905815-A9849CF3-59A1-4B6F-9C45-71CFA8FAF233Q34992608-1A00B571-DAA6-4B88-8BD8-29295AA9AAD8Q35026218-C3E91A65-285D-4C92-8531-62EDA90AB438Q35029623-1FDC8095-C3AC-4B3F-8109-B34F979BABF2Q35187425-4BF584DC-45E9-4EC7-B5AF-C1E3557F12F0Q35460295-6E802429-E0B4-493D-87F3-C8869B05EDDEQ35817721-97162999-A7A4-41DC-B137-945E6BF1360CQ35871962-D46CABE4-B234-41A9-8DDA-A55E2CBEC721Q35917143-CB9F5EE9-53D9-4D15-9892-70B36643FFBDQ35946407-96D361BB-570B-46CB-8F7D-8A76743CEE1BQ36011053-DD53A8D3-6853-4104-8ABD-20CBF5E93C1AQ36045185-D208D75B-DA5F-4C1B-B0BF-02ADB9B0F128Q36092395-8FCD1484-820B-4C3A-9C2F-8A6B9EEDF6AFQ36124203-DC6E7C03-561F-41DC-B04F-B4C1DA6E1196Q36240757-7637E45C-F25F-4891-948C-805F76A9E668Q36411656-E84E4485-12A3-4CFF-80C7-0930E438F1F7Q36443768-BB66E360-2F9B-46A6-8E84-9188CAAD0D41Q36517644-A8844AE5-8E85-4C07-9C52-7C41759F5235Q36597131-61EB40A4-E4B9-47D9-B889-602689A4A846Q36918309-19128CEB-AE62-4330-833F-4083F153DD91Q36947413-29B8BE41-323D-4D48-89AC-770CB1CE90F6Q36978025-9929A995-8AE8-40A4-955B-F8FB348BE8AAQ37254454-0CBD4295-A940-498E-A848-983922F3381AQ37387192-3C914E31-BB61-4CA8-A695-F029F4320CF4Q37435149-F660211B-7A69-4699-9594-130555BD3019Q37491763-D0E71B06-14D0-42F6-B96F-7B72A4C892AB
P2860
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@en
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@nl
type
label
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@en
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@nl
prefLabel
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@en
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@nl
P2093
P50
P1476
The Residual Risk Reduction In ...... in patients with dyslipidemia.
@en
P2093
Alberto Zambon
Christoph Wanner
Frank Sacks
Gerd Assmann
Henry N Ginsberg
Jane K Stock
Jean-Marc Lablanche
Jorge Plutzky
M John Chapman
Michel P Hermans
P304
P356
10.1016/J.AMJCARD.2008.10.002
P407
P433
P577
2008-11-01T00:00:00Z